Cariprazine Hydrochloride Patent Expiration
Cariprazine Hydrochloride is used for treating major depressive disorder, bipolar disorder, and schizophrenia. It was first introduced by Abbvie Inc
Cariprazine Hydrochloride Patents
Given below is the list of patents protecting Cariprazine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vraylar | US7737142 | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | Sep 17, 2029 | Abbvie |
| Vraylar | USRE47350 | Pharmaceutical formulations containing dopamine receptor ligands | Jul 16, 2029 | Abbvie |
| Vraylar | USRE49110 | Pharmaceutical formulations containing dopamine receptor ligands | Jul 16, 2029 | Abbvie |
| Vraylar | USRE49302 | Pharmaceutical formulations containing dopamine receptor ligands | Jul 16, 2029 | Abbvie |
| Vraylar | US7943621 | Salts of piperazine compounds as D3/D2 antagonists | Dec 16, 2028 | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cariprazine Hydrochloride's patents.
Latest Legal Activities on Cariprazine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Cariprazine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Nov, 2022 | US7943621 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Dec, 2021 | US7737142 |
| Patent Term Extension Certificate Critical
| 04 Dec, 2019 | US7737142 |
| Post Issue Communication - Certificate of Correction | 09 Jun, 2019 | US7737142 |
| Mail Certificate of Correction Memo | 05 Jun, 2019 | US7737142 |
| Certificate of Correction Memo | 04 Jun, 2019 | US7737142 |
| Notice of Final Determination -Election Required | 17 Apr, 2019 | US7737142 |
| Notice of Final Determination -Election Required | 17 Apr, 2019 | US7943621 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Nov, 2018 | US7943621 |
| FDA Final Eligibility Letter Critical
| 10 Oct, 2018 | US7737142 |
Cariprazine Hydrochloride's Family Patents
